Rifaximin oral tablet (DrugBank: Rifaximin)
7 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 0 |
65 | Primary immunodeficiency | 0 |
94 | Primary sclerosing cholangitis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
99 | Chronic intestinal pseudo-obstruction | 1 |
296 | Biliary atresia | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04118699 (ClinicalTrials.gov) | December 25, 2019 | 23/9/2019 | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial | Chronic Intestinal Pseudo-obstruction | Drug: Rifaximin oral tablet;Drug: Placebo oral tablet | Yokohama City University | ASKA Pharmaceutical Co., Ltd. | Recruiting | 20 Years | 74 Years | All | 12 | Phase 2 | Japan |